

# The Investigation of Genetic and Clinical Features in Patients with Hereditary Spastic Paraplegia in Central-Southern China

**Chen Wang**

Wuhan Union Hospital

**Yun-Jian Zhang**

Wuhan Union Hospital

**Ci-Hao Xu**

Wuhan Union Hospital

**De Li**

Wuhan Union Hospital

**Zhi-Jun Liu** (✉ [2017xh0351@hust.edu.cn](mailto:2017xh0351@hust.edu.cn))

Wuhan Union Hospital <https://orcid.org/0000-0001-6252-9477>

**Yan Wu**

Wuhan Union Hospital

---

## Research

**Keywords:** Hereditary spastic paraplegia, SPAST, SPG11, B4GALNT1

**Posted Date:** July 21st, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-43715/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Molecular Genetics & Genomic Medicine on February 27th, 2021. See the published version at <https://doi.org/10.1002/mgg3.1627>.

## Abstract

**Objective** Hereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative disorders. We describe the genetic and clinical features of a cohort of five HSP families from central-southern China.

**Methods** Using targeted exome-sequencing technology, we investigated the genetic and clinical features in five HSP families. We review the clinical histories of these patients as well as the molecular and functional characterization of the associated gene variants. We also performed functional analysis of an intron variant of *SPAST* in vitro.

**Results** We identified a known *SPAST* mutation (p.Pro435Leu) in a family with autosomal dominant HSP (AD-HSP) and four novel variants in three HSP families and a sporadic case. These identified four novel variants include a *SPG11* nonsense variant (p.Val1979Ter), two *B4GALNT1* variants (p.Ser475Phe and c.1002+2T>G), and a splicing site variant in *SPAST* (c.1245+5G>A). Minigene analysis of the *SPAST* splicing variant (c.1245+5G>A) revealed that the mutation resulted in mRNAs with a loss of exon 9. The SPG4 family carrying *SPAST* c.1245+5G>A exhibited obviously genetic anticipation, with a decreased age at onset and increased severity in successive generations. The proband with p.Val1979Ter variant in *SPG11* showed characteristic clinical feature of early-onset, severe spasticity, and corpus callosum atrophy which were highly suggestive of the diagnosis of SPG11-associated HSP.

**Conclusions** Our findings strongly support variable phenotype of *B4GALNT1*-related SPG26 and also expand the clinical and mutation spectrum of HSP caused by mutations in *SPG4*, *SPG11*, and *B4GALNT1*. These results will help to improve the efficiency of early diagnosis in patients clinically suspected of HSP.

## Background

Hereditary spastic paraplegias (HSPs) are a heterogeneous group of genetically determined neurodegenerative disorders characterized by progressive weakness and spasticity in the lower limbs. Clinically, HSPs have been divided into pure and complicated forms, based on the manifestation of additional features, such as ataxia, intellectual disability, dysarthria, extrapyramidal disturbance, and peripheral neuropathy. The disease can occur at any age, but it most commonly affects children between 3 and 15 years. It affects individuals of diverse ethnic groups with significantly variable prevalence estimates ranging from 2 to 10 per 100,000(1).

HSP can be inherited in an autosomal dominant (AD-HSP), autosomal recessive (AR-HSP), X-linked manner (XL-HSP), as well as mitochondrial maternal transmission. To date, more than 60 genes or sites have been identified, of which *SPAST* (previously known as SPG4) and *SPG11* appear to be the most common genetic cause of the AD-HSP and autosomal recessive disease, respectively (2, 3).

We have recently performed comprehensive genetic investigations in Chinese HSP patients and also found that SPG4 and SPG11 were the most frequent form of AD-HSP and AR-HSP in southeast China, respectively(4, 5). However, there are still very few reports on genetic analysis of HSP patients in central-southern China. In this study, we conducted a targeted exome-sequencing in five independent families with HSP from central-southern region of China, to enrich the profile of genes mutated and clinical features of Chinese HSP patients. To our knowledge, this is the first report of mutation in *B4GALNT1* gene, also known as SPG26, in Chinese patient with HSP. Being able to define the genetic and clinical profile of SPG26-associated HSP may improve understanding in disease heterogeneity and severity.

## Materials And Methods

### Subjects

13 patients from 5 unrelated Chinese HSP pedigrees, include 5 probands and 8 affected family members, were recruited for the study. All the patients were evaluated by at least two senior neurologists and diagnosed according to Harding's criteria. They are mainly from central-southern region of China (Han Chinese) and collected from the Neurology Department of Wuhan Union hospital, between September 2017 and October 2019. DNA samples were obtained from all the subjects, including the probands, as well as affected and unaffected family members. Blood biochemical analysis, electromyogram (EMG) and Nerve conduction tests (NCT), and magnetic resonance imaging (MRI) of brain and spinal cord were conducted. An additional 200 normal individuals were included as controls after exclusion of the occurrence of common neurological disorders. Written informed consents were obtained from all participants. This study was approved by the ethics committee of Wuhan Union Hospital(reference number:2019-S1136).

### Genetic analysis

Genomic DNA was extracted from peripheral blood samples using Blood Genomic Extraction Kit (Qiagen, Germany). A panel was designed to cover 261 genes, including 67 known genes responsible for dominant and recessive HSP forms and other 194 genes associated with spastic paraplegia (**Table S1**). Deep sequencing was performed using Illumina HiSeq2000 system (GrandOmics Biosciences Co, China). The annotation and analysis of sequenced reads were performed as we described previously(6). Sanger sequencing was used to validate the candidate variants after data analysis. Co-segregation analysis was conducted through screening for the confirmed variants in the family members. In order to further screen for large deletions or duplications of culprit genes (*SPAST*, *ATL1*, *REEP1*, *PGN*, and *SPG11*), the Multiplex ligation-dependent probe amplification assay (MLPA) analysis were performed as we described previously(4). Moreover, analysis of trinucleotide repeats in SCA 1, 2, 3, 6, 7, 12 and 17, as well as Dentatorubral-pallidoluysian atrophy (DRPLA), which could not be detected by targeted sequencing analysis, was conducted via repeat-primed PCR combined with fragment length analysis.

## Minigene analysis

Constructions of minigene was based on the pSPL3 exon trapping vector (Invitrogen, USA). The SPAST exons relevant to the splicing variant (c.1245 + 5G > A) along with flanking intronic sequences were amplified by PCR of genomic DNA from the patient and control, with primers containing restriction sites for XhoI and EcoRI (5'-GGTACGGGATCACCAGAATTCACCTGGCCTCATAGCTTAC-3'(forward) and 5'-ATCCTGCAGCGGCCGCTCGAGCTGATGTTAAGCCAGCCAG-3'(reverse). The PCR products were then cloned into the splicing reporter pSPL3 vector and transfected into HEK293T cells. The RNA extraction and RT-PCR was performed using the RNAiso Plus and PrimeScript RT reagent kit (Takara, Japan), respectively. Electrophoresis and sanger sequencing were used for splicing pattern analysis.

## Results

### Genetic findings

In general, about 97.5% of the target bases were covered with at least 50X per individual, and the mean depth of coverage for all target regions was 185. After filtering and validation by Sanger sequencing, 5 probable pathogenic variants were identified in 4 probands, involving one variant previously reported as pathogenic variant and four novel variants. The known pathogenic variant c.1304C > T (p.Pro435Leu) was identified in *SPAST* gene. The identified four novel variants include two *B4GALNT1* variants (p.Ser475Phe and c.1002 + 2T > G), a *SPG11* p.Val1979Ter nonsense variant, and a splicing site variants in *SPAST* (c.1245 + 5G > A)(Fig. 1). All of these variants, being predicted as harmful effects by the SIFT, PolyPhen-2, dbSNV and Human Splicing Finder (HSF) software, were absent in publicly available database as well as 200 normal controls. According to the ACMG standards and guidelines, all four variants were classified as likely pathogenic variants. The novel splicing mutation (c.1245 + 5G > A) in *SPAST* was co-segregated perfectly with the phenotypes observed in family 2. Moreover, pathogenic repeat expansions which are implicated in all SCA types (SCA types 1–3, 6, 7, 12, and 17) and DRPLA, as well as large deletions or duplications of HSP culprit genes (*SPAST*, *ATL1*, *REEP1*, *PGN*, and *SPG11*), was excluded in this family. The two novel *B4GALNT1* variants identified in compound heterozygous state, including a splicing mutation site (c.1002 + 2T > G) and a missense mutation (p.Ser475Phe), were found to segregate with the disease in family 3. In family 4, co-segregation analysis showed that the father and mother are both heterozygous for the novel *SPG11* p.Val1979Ter variant.

### Splicing pattern analysis

A splicing reporter minigene with *SPAST* exon 9 was constructed (Fig. 3). Agarose gel electrophoresis of RT-PCR showed that the fragment obtained in mutant group was smaller than that obtained in control group (Fig. 3). Sanger sequencing revealed that the *SPAST* c.1245 + 5G > A mutation resulted in mRNAs with a loss of exon 9 (Fig. 3).

### Clinical manifestations of probands

The clinical manifestations of all probands are summarized in Table 1, and pedigrees of the families are displayed in Fig. 2. In total we recruited 13 affected individuals from 5 independent families, include 8 males and 5 females. The mean age at onset was 30.23 years, ranging from 7 to 48 years. Among the five probands, two showed an AD inheritance pattern, two with an AR inheritance pattern, and one was a sporadic case. Apart from the most common symptoms of progressive lower limbs weakness and spasticity, additional presentations including dysarthria, dysphagia, urinary incontinence, constipation, and intelligence impairment were also observed in present study.

Table 1  
The clinical presentations and genetic analysis results of 5 HSP probands.

Proband no	Sex	AAO (y)	Inheritance	LL weakness	LL plasticity	Reflexia	Intellectual disability	EMG/NCT	Brain MRI	Additional features	Gene	Pat var
1	F	48	AD	+	+	++++	-	normal	normal	dysarthria	<i>SPAST</i>	p.P
2	M	26	AD	+	+	++++	-	normal	normal	constipation	<i>SPAST</i>	c.1: >A
3	M	7	AR	+	+	++++	+	normal	normal	poor social communication skills	<i>B4GALNT1</i>	p.S c.11 >G
4	M	12	sporadic	+	+	+++	+	normal	thin corpus callosum	urinary dysfunction, dysarthria, dysphagia	<i>SPG11</i>	p.V
5	M	41	AR	+	+	++++	-	normal	normal	-	-	-

F, female. M, Male. LL, Lower limb. AAO, Age at onset. AD, autosomal dominant. AR, autosomal recessive. EMG, electroneuromyography. NCT, nerve conduction absent.

## Characteristics of HSP patients with *SPAST* mutations

The proband (II:2) in family 1, carrying *SPAST* p.Pro435Leu variant, was a 56-year-old male and presented with lower limbs weakness and gait disturbance at the age of 48. As the disease progresses, he began to show dysarthria and severe spasticity in the lower limbs. He currently needs to move around with the aid of crutch. No signs of intellectual disability were observed in the proband. Neurological examination showed hyperactive deep tendon reflexes in the lower limbs, gait ataxia, pes cavus, and positive Babinski signs. The EMG results and Brain MRI were unremarkable. His mother (I:2) developed the illness at the age of 50 with a disease duration of 9 years.

The proband (III:4) in family 2, a 36-year-old female, was detected as the carrier of *SPAST* c.1245 + 5G > A variant. She presented with lower limbs weakness and an unsteady gait at the age of 26. As the disease progresses, her gait disturbance became more severe with frequent falling. She had constipation problems since age 31. Severe spasticity was marked in the lower limbs although the early-stage of baclofen treatment was taken to the proband. Her examination was further marked by hyperactive deep tendon reflexes and positive Babinski signs, with mild rigidity in all extremities especially in the lower limbs. She was bilateral pes cavus and ankle clonus. Her older sister (III:3) experienced the similar symptoms at the age of 26. The proband's mother (II:6) and other three affected uncles (II:3, III:4, III:5) presented with gait disturbance or walking difficulty at the age of 42, 44, 45 and 44, respectively. The proband's grandmother (I:2) was diagnosed with HSP when she was 50 years old and died at the age of 70 years. The proband's daughter (III:2) had initial symptom of gait disturbance at age 7 years and experienced mild cognitive impairment, with a Mini-Mental State Exam (MMSE) score of 22/30, eight years after symptom onset. She had poor concentration and social communication skills. No muscular atrophy or fasciculation was observed in all affected individuals within this family. Upon neurological examination, these patients revealed moderate or severe spasticity in the lower limbs, pyramidal-tract signs, and gait ataxia. The Brain and spinal cord MRI were normal. The EMG and nerve conduction test were also unremarkable.

## Presentations of HSP patients with *B4GALNT1* mutations

The proband (II:3) from family 3 carrying the *B4GALNT1* c.1002 + 2T > G and c.1424C > T (p.Ser475Phe) variants presented with subtle gait abnormalities at the age of 7 years. His gait disturbance was gradually observed as disease progresses, when he began to experience severe spasticity in the lower limbs. He had learning disability with poor academic performance and social communication skills. Muscle weakness and atrophy was not obviously observed in proximal limbs, but with a slightly reduced power of 4 to 5/5 and atrophy in the distal areas. His sensory, cerebellar, and sphincter function were not affected. Neurological examination at the age of 15 years showed severe spasticity in the lower limbs, exaggerated reflexes, pes cavus and pyramidal tract signs. Cerebral and spinal MRI showed no significant changes in the brain and spinal cord. Nerve conduction tests and EMG were unremarkable. His older brother (II:2), aged 28 years old, experienced the similar symptoms at the age of 8 years. He developed gait abnormality and severe lower limb spasticity. He is currently ambulatory with wheelchair assistance. He was unable to interact normally with others. His cognitive function declines significantly, with a Mini-Mental State Exam (MMSE) score of 5/30. Examination showed severe spasticity and weakness in the lower limbs, severe muscle atrophy involving the whole body, exaggerated reflexes, pes cavus and severe pyramidal tract signs. Consanguinity was not reported in the family.

## Characteristics of HSP patients with *SPG11* mutations

The proband (II:2) from family 4 carrying the *SPG11* mutation (p.Val1979Ter) initially experienced gait disturbance at the age of 12 years. She showed an ataxic gait and frequently fell down. Three years after these symptoms, she complained progressive lower limb weakness, dysarthria, dysphagia, intellectual disability and urinary dysfunction occasionally. She was wheelchair-bound by April 2018. Neurological examination showed spasticity in the lower limbs, ataxic gait, increased muscle tone, hyperactive deep tendon reflexes, and positive Babinski signs. No muscular atrophy or fasciculation was observed. Brain MRI showed an abnormally thin corpus callosum. Nerve conduction tests and EMG revealed no evidence of neurological disturbance. No history of neurologic disease was found in this family. It was noteworthy that her parents were non-consanguineous.

## Discussion

Using targeted exome-sequencing technology, we investigated the profile of genes mutated and clinical features in five unrelated HSP families in central-southern China. We detected a known *SPAST* p.Pro435Leu mutation and four novel likely pathogenic variants including two *B4GALNT1* variants (p.Ser475Phe and c.1002 + 2T > G), a *SPG11* p.Val1979Ter nonsense variant, and a splicing site variants in *SPAST* (c.1245 + 5G > A). All of these novel variants were first described. No causative variants were found in family 5, which suggests that whole-exome or whole-genome sequencing should be further performed to explore the new potential genes associated with the disease.

SPG4-associated HSP may exhibit high interfamilial and intrafamilial phenotypic variability including age at onset and disease severity(7). Apparent genetic anticipation has been reported in a few SPG4-associated HSP families(8–10). None of pathogenic trinucleotide-repeats expansion, often responsible for genetic anticipation of repeat expansion diseases, were described in SPG4 or other types HSPs. In line with previous study, the SPG4 family in present study showed obviously genetic anticipation, with a decreased age at onset and increased severity in successive generations. In family 2, the mean age of onset of HSP was 50, 44, 26, and 7 years in members of the first, second, third, and fourth generations of this family, respectively. It is noteworthy that the age at onset was decreased with each subsequent generation ( $P < 0.05$ ). In particular, among the second-generation family members, all 4 affected individuals experienced the disease at between 42 and 45 years of age, whereas the only affected individual in the fourth generation initially presented her first manifestation at 7 years of age. Remarkably, the only patient (III:2) in the fourth generation was younger at onset and had a more severe gait disturbance accompanied by mental impairment than the previous generations. In addition to SPG4, genetic anticipation have also been reported in other types of HSPs, such as SPG3(11) and SPG31(12). There may be other environmental and genetic modifiers influencing phenotype variability. An epistatic effect between DPY30 and *SPAST* was previously reported, which affects age at onset in a cohort of SPG4-related HSP patients(13).

SPG26-related HSP cases have been reported worldwide but mainly distribute in Europe, South America, and North America. In total 13 pathogenic variants of *B4GALNT1*, including a splicing mutation, 7 missense mutations and 5 inserts/deletions mutations, have already been reported in 14 SPG26-related HSP families with variable complicated phenotypes(14–18). To our knowledge, this is the first description of *B4GALNT1* mutations in Chinese patient with HSP. Mutations in *B4GALNT1* were also reported to in relation to autism spectrum disorder as well as cerebellar ataxia(19, 20). The clinical features of all published SPG26 cases with *B4GALNT1* mutation are summarized in **Table S2**. Altogether, patients with *B4GALNT1* mutation has a mean age at onset of 9.15 years, ranging from 1.3 to 39 years. In line with previous studies, our findings strongly support complicated phenotypic features of SPG26-related HSP characterized by slowly progressive lower limbs spasticity, early-onset, mental retardation, cognitive impairment, and extrapyramidal features. None of evidence of peripheral neuropathy was observed in present case. Therefore, *B4GALNT1* mutation should be explored in AR-HSP patients with early age at onset and intellectual deficit. *B4GALNT1* is a Golgi-residing enzyme with type II membrane topology and its mutation may result in a deficiency of GM2/GD2 synthase. The specific role of GM2/GD2 synthase deficiency in complicated phenotype of HSP remains unclear and further studies are needed to elucidate the mechanism.

*SPG11* is the most common cause of AR-HSP and more than 36 mutations in *SPG11* have already been reported in Chinese HSP patients. In this study we identified a novel homozygous insertion mutation (p.Val1979Ter) in *SPG11* gene which resulted in premature protein termination. Although this variant, in dbSNP reporting for rs749652788, has not been reported in individuals with an SPG11-related disease, it was still considered as pathogenic variant based on its predicted impact on SPG11 protein. Our study showed that this variant was co-segregated perfectly with the phenotypes of SPG11-related HSP patients, which strongly support its pathogenicity. SPG11-associated HSP are often characterized by early-onset, lower limbs spasticity, dysarthria, cognitive decline, peripheral neuropathy, and thin corpus callosum(21, 22). In the present case, although no signs of cognitive impairment and peripheral neuropathy was observed, the characteristic clinical feature of early-onset, severe spasticity, and corpus callosum atrophy are highly suggestive of the diagnosis of SPG11-associated HSP.

## Conclusion

we detected a known disease-causing variant in *SPAST* gene and four novel likely pathogenic variants in *SPAST*, *SPG11*, and *B4GALNT1*, respectively. Our findings expand the clinical and mutation spectrum of HSP caused by mutations in these genes. These results will help to improve the efficiency of early diagnosis in patients clinically suspected of HSP.

## Abbreviations

**HSP:** Hereditary spastic paraplegia

**AD:** autosomal dominant

**AR:** autosomal recessive

**XL:** X-linked manner

**EMG:** electromyogram

**NCT:** Nerve conduction tests

**MRI:** magnetic resonance imaging

**MLPA:** Multiplex ligation-dependent probe amplification assay

**DRPLA:** Dentatorubral–pallidoluysian atrophy

**MMSE:** Mini-Mental State Exam

## Declarations

## Availability of data and materials

All data used for analysis are shown in the figures and tables in this article. Data sharing is applicable to this article if requested by other investigations for purposes of replicating the results.

## Acknowledgements

We would like to thank all the subjects for their help and active participation in this study. We thank the reviewers for the comments and suggestions.

## Funding information

This work was supported by the grant from the National Natural Science Foundation to Yan Wu (81471202, Beijing).

## Contributions

WC, ZYJ and LZJ conceived and designed the content of the paper. WC, ZYJ were involved in data collection, data interpretation and contributed equally to the first draft. XCH and LD contributed to literature search. WC, ZYJ, XCH and LD wrote the manuscript. LZJ and WY revised the paper and all authors read and approved the manuscript.

## Ethics declarations

### Ethics approval and consent to participate

This study was approved by the ethics committee of Tongji Medical School (reference number: 2019-S1136) in accordance with the recommendations from the Declaration of Helsinki. Written informed consents were obtained from all participants.

### Consent for publication

Each patient or patient's parent signed consent for publication.

### Conflicts of Interest


The authors declare no conflict of interest.

## References

1. Ruano L, Melo C, Silva MC et al. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. *Neuroepidemiology* 2014; 42: 174-183.
2. Boutry M, Morais S, Stevanin G. Update on the Genetics of Spastic Paraplegias. *Current neurology and neuroscience reports* 2019; 19: 18.
3. Klebe S, Stevanin G, Depienne C. Clinical and genetic heterogeneity in hereditary spastic paraplegias: from SPG1 to SPG72 and still counting. *Rev Neurol (Paris)* 2015; 171: 505-530.
4. Lu C, Li LX, Dong HL et al. Targeted next-generation sequencing improves diagnosis of hereditary spastic paraplegia in Chinese patients. *J Mol Med (Berl)* 2018; 96: 701-712.
5. Wei Q, Dong HL, Pan LY et al. Clinical features and genetic spectrum in Chinese patients with recessive hereditary spastic paraplegia. *Translational neurodegeneration* 2019; 8: 19.
6. Liu ZJ, Lin HX, Wei Q et al. Genetic Spectrum and Variability in Chinese Patients with Amyotrophic Lateral Sclerosis. *Aging Dis* 2019; 10: 1199-1206.
7. Tesson C, Koht J, Stevanin G. Delving into the complexity of hereditary spastic paraplegias: how unexpected phenotypes and inheritance modes are revolutionizing their nosology. *Hum Genet* 2015; 134: 511-538.
8. Reddy PL, Seltzer WK, Grewal RP. Possible anticipation in hereditary spastic paraplegia type 4 (SPG4). *Can J Neurol Sci* 2007; 34: 208-210.
9. Lan MY, Fu SC, Chang YY et al. Clinical and genetic analysis of four Taiwanese families with autosomal dominant hereditary spastic paraplegia. *J Formos Med Assoc* 2012; 111: 380-385.
10. Kawarai T, Montecchiani C, Miyamoto R et al. Spastic paraplegia type 4: A novel SPAST splice site donor mutation and expansion of the phenotype variability. *J Neurol Sci* 2017; 380: 92-97.
11. Ming L. [SPG3A-hereditary spastic paraplegia with genetic anticipation and incomplete penetrance]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2007; 24: 15-18.
12. Kamada M, Kawarai T, Miyamoto R et al. Spastic paraplegia type 31: A novel REEP1 splice site donor variant and expansion of the phenotype variability. *Parkinsonism Relat Disord* 2018; 46: 79-83.
13. Newton T, Allison R, Edgar JR et al. Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia. *Brain : a journal of neurology* 2018; 141: 1286-1299.
14. Boukhris A, Schule R, Loureiro JL et al. Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. *Am J Hum Genet* 2013; 93: 118-123.
15. Harlalka GV, Lehman A, Chioza B et al. Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. *Brain : a journal of neurology* 2013; 136: 3618-3624.
16. Wakil SM, Monies DM, Ramzan K et al. Novel B4GALNT1 mutations in a complicated form of hereditary spastic paraplegia. *Clinical genetics* 2014; 86: 500-501.
17. Dad R, Walker S, Scherer SW et al. Febrile ataxia and myokymia broaden the SPG26 hereditary spastic paraplegia phenotype. *Neurol Genet* 2017; 3: e156.
18. Rose L, Hall K, Tang S et al. Homozygous B4GALNT1 mutation and biochemical glutaric acidemia type II: A case report. *Clin Neurol Neurosurg* 2020; 189: 105553.
19. Iossifov I, O'Roak BJ, Sanders SJ et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014; 515: 216-221.


20. Fogel BL, Lee H, Deignan JL et al. Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia. *JAMA Neurol* 2014; 71: 1237-1246.
21. Pensato V, Castellotti B, Gellera C et al. Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. *Brain : a journal of neurology* 2014; 137: 1907-1920.
22. Stevanin G, Azzedine H, Denora P et al. Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. *Brain : a journal of neurology* 2008; 131: 772-784.

## Figures




**Figure 1**

Chromatograms of four novel variants identified in SPAST, SPG11, and B4GALNT1 gene, respectively. A. The SPAST c.1245+5G>A variant from family 2. B. The SPG11 p.Val1979Ter variant from family 4. C. The B4GALNT1 p.Ser475Phe variants from family 3. D. The B4GALNT1 c.1002+2T>G variants from family 3.



**Figure 2**  
 Pedigrees of five HSP patients in present study. Squares indicate males; circles indicate females; filled symbols indicate affected individuals; diagonal lines across symbols indicate deceased individuals; arrows indicate the probands; "+/+" indicate two mutant alleles; "+/-" or "-/+" indicate mutation occurring in one of two alleles; "-/-" indicate two wild type alleles; "\*" indicate the DNA sample was not available.



**Figure 3**

Results of minigene splicing assay for the SPAST c.1245+5G>A variant. (A) cDNA products were separated by agarose gel electrophoresis. Lane1: WT [263 bp + 72bp (exon 9)]; Lane2: c.1245+5G>A variant [263 bp]; Lane3: DNA Marker. (B) Schematic diagram of splicing reporter minigene construction. Splice donor (SD) and splice acceptor (SA) are two exons of the pSPL3 vector. (C) The sequencing results for the bands after electrophoresis.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarytable2.doc](#)
- [Supplementarytable1.xls](#)